A 2025 clinical trial of ALZ-801 (valiltramiprosate) involving more than 300 adults age 50 or older who were genetically predisposed to Alzheimer's found that a subgroup of 125 participants with mild cognitive impairment at baseline showed a 52% slower rate of cognitive decline on one measured outcome compared with placebo.
October 29, 2025
high
statistical
Subgroup efficacy result from a 2025 randomized clinical trial of ALZ-801.